Roche Has “Reasonable” Chance Of Launching Its Long-Acting EPO In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche believes is has a "reasonable" chance of being able to launch its long-acting EPO product CERA in the U.S. upon approval despite expected patent challenges, the company said Sept. 13 at the Bear Stearns health care conference in New York.